7Neuromodulation and Bimodal Stimulation

FThe neuromodulation premise

Sound therapies work indirectly, by feeding the auditory system and letting the brain adapt. Neuromodulation is more direct: it uses magnetic, electrical or paired sensory stimulation to alter the abnormal neural activity — chiefly the pathological hyperactivity and synchrony — that is thought to underlie the tinnitus percept. The shared goal across these methods is to desynchronise or recalibrate maladaptive circuits rather than merely cover the sound.

These approaches range from clinic-based brain stimulation to home-based wearable devices, and they differ sharply in their evidence. Some remain firmly experimental; one has reached regulatory clearance and routine use. Understanding which is which is the core clinical skill of this module.

TrTMS and tDCS: stimulating the cortex

Repetitive transcranial magnetic stimulation (rTMS) applies magnetic pulses over the auditory cortex to suppress cortical hyperactivity. Trials have shown short-term reductions in tinnitus severity in selected patients, but a large, well-controlled randomised trial by Folmer and colleagues found only modest benefit, with responders not reliably predictable and effects that tended to wane [2015].

Transcranial direct current stimulation (tDCS) delivers weak constant current, often over the dorsolateral prefrontal or auditory cortex, aiming to nudge cortical excitability. A systematic review and meta-analysis found small, short-term effects on tinnitus distress with considerable heterogeneity and an unresolved optimal protocol [2022]. Both rTMS and tDCS are best regarded as research tools or adjuncts, not standalone treatments.

TVagus-nerve-paired tones

A more targeted idea is to harness activity-dependent plasticity. Vagus nerve stimulation (VNS) releases neuromodulators that gate cortical plasticity; if vagal pulses are paired in time with tones away from the tinnitus frequency, the auditory map may be reshaped to reduce the over-representation of the tinnitus frequency.

Tyler and colleagues ran a prospective randomised double-blind pilot of VNS paired with tones and found reductions in tinnitus measures in a subgroup, supporting feasibility while underscoring that the effect is partial and that the implanted-VNS approach is invasive [2017]. VNS-paired-tone therapy remains investigational and is not in routine clinical use.

CBimodal stimulation: the breakthrough that reached the clinic

The most clinically significant development is bimodal auditory-somatosensory stimulation, which pairs sound with timed somatosensory input to exploit spike-timing-dependent plasticity in the dorsal cochlear nucleus. Shore’s group showed in guinea pigs and humans that precisely timed auditory-plus-somatosensory pairing can desynchronise the fusiform-cell circuitry and reduce tinnitus [2018], and a subsequent controlled clinical trial of their device confirmed reduced tinnitus loudness and severity with the optimally timed bimodal pairing [2023].

In parallel, Conlon and colleagues developed a device pairing sound with tongue stimulation. The large TENT-A1 trial reported significant reductions in tinnitus questionnaire scores sustained over 12 months [2020], and the follow-up TENT-A2 trial showed that the stimulation parameters could be sequenced for continued benefit [2022]. This device (marketed as Lenire) received FDA clearance in 2023, making bimodal stimulation the first neuromodulation approach to reach mainstream regulatory approval for tinnitus.

CStatus, evidence and counselling

The hierarchy is now reasonably clear. Bimodal auditory-somatosensory stimulation has the strongest evidence, with large randomised trials and regulatory clearance; rTMS and tDCS have small, short-lived effects and remain adjuncts or research procedures; VNS-paired tones remain investigational and invasive. None is a cure, and even the bimodal devices help a substantial fraction — not all — of users, with benefits that build over weeks of daily use [2013].

When counselling patients, it is fair to say that bimodal stimulation is an evidence-backed, FDA-cleared option for chronic subjective tinnitus, that the expected effect is a meaningful reduction in distress rather than silence, and that consistent daily use over the prescribed programme is essential. Patients should be steered away from clinics marketing rTMS or tDCS as proven tinnitus cures [2014].